Rivastigmine Hydrogen Tartrate
Rivastigmine Hydrogen Tartrate Brand names, Rivastigmine Hydrogen Tartrate Analogs
Rivastigmine Hydrogen Tartrate Brand Names Mixture
- No information avaliable
Rivastigmine Hydrogen Tartrate Chemical_Formula
C14H22N2O2
Rivastigmine Hydrogen Tartrate RX_link
http://www.rxlist.com/cgi/generic2/rivastig.htm
Rivastigmine Hydrogen Tartrate fda sheet
Rivastigmine Hydrogen Tartrate msds (material safety sheet)
Rivastigmine Hydrogen Tartrate Synthesis Reference
No information avaliable
Rivastigmine Hydrogen Tartrate Molecular Weight
250.337 g/mol
Rivastigmine Hydrogen Tartrate Melting Point
No information avaliable
Rivastigmine Hydrogen Tartrate H2O Solubility
No information avaliable
Rivastigmine Hydrogen Tartrate State
Solid
Rivastigmine Hydrogen Tartrate LogP
2.611
Rivastigmine Hydrogen Tartrate Dosage Forms
Capsule; Solution
Rivastigmine Hydrogen Tartrate Indication
For the treatment of mild to moderate Alzheimer's disease.
Rivastigmine Hydrogen Tartrate Pharmacology
Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Rivastigmine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Pathological changes in Dementia of the Alzheimer type involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways are thought to be intricately involved in memory, attention, learning, and other cognitive processes. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact.
Rivastigmine Hydrogen Tartrate Absorption
No information avaliable
Rivastigmine Hydrogen Tartrate side effects and Toxicity
No information avaliable
Rivastigmine Hydrogen Tartrate Patient Information
Caregivers should be advised of the high incidence of nausea and vomiting associated with the use of the drug along with the possibility of anorexia and weight loss. Caregivers should be encouraged to monitor for these adverse events and inform the physician if they occur. It is critical to inform caregivers that if therapy has been interrupted for more than several days, the next dose should not be administered until they have discussed this with the physician.
Rivastigmine Hydrogen Tartrate Organisms Affected
Humans and other mammals
